Hyperliquid Strategies expands token‑buying facility to $2.5 billion

Nasdaq‑listed Hyperliquid Strategies has increased its committed‑equity financing facility with Chardan Capital Markets from $1 billion to $2.5 billion. The expansion gives the company additional optional funding to purchase its native HYPE token, but the amount available for discounted share sales is limited by recent filings.

Current utilization of the facility

The company’s annual report shows $646.6 million of gross proceeds through June 30, plus an additional $117.1 million raised after quarter‑end, totaling at least $763.7 million. This leaves roughly $236.3 million of the original $1 billion threshold before a Nasdaq‑imposed cap on discounted share issuances would apply.

Nasdaq dilution cap

Under an amendment, Hyperliquid Strategies cannot issue shares at prices below $12.02 if the aggregate number of such shares would exceed 42,641,847, representing 19.99 % of the company’s pre‑amendment voting power. Issuances above $12.02 are not subject to this cap, and any reduction of the cap requires stockholder approval unless exempt under Nasdaq rules.

Impact on HYPE token purchases

In an August 27 update, the firm disclosed that it had spent $773.4 million to acquire about 16.5 million HYPE tokens and held roughly 29.3 million HYPE in total. The $2.5 billion facility therefore provides optional financing capacity, not a guaranteed purchase program. Access to the full commitment beyond the $1 billion trigger depends on share‑sale prices, remaining cap headroom, and possible shareholder approval.

Key takeaways

• Facility increased to $2.5 billion, but only $236.3 million remains before a $1 billion dilution threshold.
• Discounted share sales are limited to 42,641,847 shares priced below $12.02, or 19.99 % of pre‑amendment voting power.
• Shares sold at $12.02 or higher are not subject to the cap.
• Company has already deployed $773.4 million to buy ~16.5 million HYPE tokens.
• Further financing depends on sale prices and potential shareholder approval.